Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

March 21, 2023

IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting

March 15, 2023

CEO, Dr. Corinne LeGoff interviewed on Fox Business

March 2, 2023

Financial Events

Imunon, Inc. Third Quarter 2022 Earnings Call

November 14, 2022 at 11:00 AM EST

Imunon Corporation Presentation_Chardan’s 6th Annual Genetic Medicines Conference

October 3, 2022 at 2:30 PM EDT